Indivior Pharmaceuticals (INDV) Enterprise Value (2021 - 2026)

Indivior Pharmaceuticals' Enterprise Value history runs 6 years deep, the most recent figure standing at -$175.0 million for Q1 2026.

• On a quarterly basis, Enterprise Value rose 53.08% year-over-year to -$175.0 million in Q1 2026; TTM through Mar 2026 was -$175.0 million, a 53.08% increase from a year earlier, with the FY2025 full-year figure at -$195.0 million, up 39.06% from the prior year.
• Enterprise Value climbed to -$175.0 million in Q1 2026 per INDV's latest filing, from -$195.0 million in the prior quarter.
• Across five years, Enterprise Value topped out at -$175.0 million in Q1 2026 and bottomed at -$893.0 million in Q4 2022.
• The 5-year median for Enterprise Value is -$391.5 million (2023), against an average of -$415.1 million.
• Across the five-year window, Enterprise Value gained 18.97% in 2022 and surged 54.09% in 2023, its largest moves.
• Year by year, Enterprise Value stood at -$893.0 million in 2022, then surged by 54.09% to -$410.0 million in 2023, then gained by 21.95% to -$320.0 million in 2024, then surged by 39.06% to -$195.0 million in 2025, then advanced by 10.26% to -$175.0 million in 2026.
• Per Business Quant, the three latest INDV Enterprise Value figures stand at -$175.0 million (Q1 2026), -$195.0 million (Q4 2025), and -$445.0 million (Q3 2025).